<DOC>
	<DOCNO>NCT00367952</DOCNO>
	<brief_summary>The study examine safe effective apricitabine give long term ( ongoing treatment ) HIV patient already complete AVX-201 trial</brief_summary>
	<brief_title>A Long Term , Safety Study Apricitabine HIV-infected Subjects</brief_title>
	<detailed_description>An ongoing study ( AVX-201 ) examine safety efficacy apricitabine compare 3TC HIV patient fail therapy contain 3TC presence M184V mutation reverse transcriptase . This extension study ( AVX-201E ) available patient complete AVX-201 protocol . Patients continue receive apricitabine open label 96 week ( make total 144 week start AVX-201 ) addition optimise background . Safety marker efficacy marker follow .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Completed AVX201 protocol , Plasma HIV RNA &lt; 5000 copies/ml , CD4 cell &gt; 50 Pregnant breastfeeding female , withdrawal AVX201</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>apricitabine</keyword>
	<keyword>drug resistance</keyword>
	<keyword>reverse transcriptase</keyword>
	<keyword>lamivudine</keyword>
</DOC>